Cosentyx’s IL-17A mechanism provides a differentiated approach for HS in younger patients.
On Friday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s NVS Cosentyx (secukinumab) for younger patients ...
Swiss pharma giant Novartis late Friday announced today that Cosentyx (secukinumab) received US Food and Drug Administration ...
Zacks Investment Research on MSN
FDA approves NVS' Cosentyx in hidradenitis suppurativa for adolescents
Novartis NVS announced that the FDA approved a label expansion of psoriasis drug Cosentyx. The regulatory body approved the ...
Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval ...
The approval was based on data from the phase 3 SUNSHINE and SUNRISE trials, which included 1084 adults with moderate to severe HS. Results showed a significantly greater proportion of patients ...
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagn ...
FDA approval based on robust Phase III data in which Cosentyx ® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 2 1 As the only IL-17A inhibitor ...
US FDA approves Novartis Cosentyx for paediatric patients aged 12+ with moderate to severe hidradenitis suppurativa: Basel Monday, March 16, 2026, 14:00 Hrs [IST] Novartis announc ...
The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results